PPCB — Propanc Biopharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1517681 ·
Last close
$1.74
Market Cap
$3.96M
52W High
$5.12
52W Low
$1.56
ADV30
207,951
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -6,400,221 | -6,360,336 | 14,333,780 | 443,702 | 3,505,895 |
| Dec 2025 | 0 | — | -3,654,734 | -3,091,394 | 15,111,532 | 561,237 | 3,659,267 |
| Sep 2025 | 0 | — | -4,673,564 | -4,837,738 | 17,975,681 | 602,737 | 3,614,514 |
| Jun 2025 | 0 | — | -3,645,246 | -4,071,461 | 19,631,808 | 12,088 | 5,725,616 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-3,126,589
Investing CF
$-4,758
Financing CF
$3,712,112
CapEx
$-4,758
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-45.42
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-134,482,898
Inventory
—
Receivables
$16,994
ST Investments
—
EBIT TTM
$-65,344,751
Pretax Income TTM
$-66,067,939
Interest Exp TTM
$723,188
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -57,278,131 | -58,923,300 | 19,631,808 | 5,725,616 | — | -405,168 |
| Jun 2024 | 0 | -1,536,049 | -1,820,528 | 72,365 | 3,851,424 | — | -935,118 |
| Jun 2023 | 0 | -1,776,645 | -2,660,566 | 60,328 | 3,177,507 | — | -1,105,251 |
| Jun 2022 | 0 | -1,990,870 | -2,658,087 | 81,651 | 3,105,300 | — | -1,436,304 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SXTP | 60 DEGREES PHARMACEUTICALS, INC. | $3.99M | $1.50 | — |
| ARTL | ARTELO BIOSCIENCES, INC. | $3.99M | $1.71 | — |
| DCOY | Decoy Therapeutics Inc. | $4.06M | $7.63 | — |
| XRTX | XORTX Therapeutics Inc. | $4.10M | $2.37 | — |
| REVB | REVELATION BIOSCIENCES, INC. | $4.14M | $1.06 | — |
News headlines (Yahoo Finance, 1h cache)
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
2026-05-20 12:45 · Yahoo
Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients
2026-05-19 12:45 · Yahoo
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
2026-05-15 12:45 · Yahoo
Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans
2026-05-14 02:00 · Yahoo
Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain
2026-03-24 12:45 · Yahoo
Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy
2026-03-12 12:45 · Yahoo
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
2026-03-10 12:45 · Yahoo
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
2026-03-03 13:45 · Yahoo
Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results
2026-02-18 13:45 · Yahoo
Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market
2026-02-05 13:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.